PMID- 36980321
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230331
IS  - 2075-4418 (Print)
IS  - 2075-4418 (Electronic)
IS  - 2075-4418 (Linking)
VI  - 13
IP  - 6
DP  - 2023 Mar 7
TI  - Key Members of the CmPn as Biomarkers Distinguish Histological and Immune 
      Subtypes of Hepatic Cancers.
LID - 10.3390/diagnostics13061012 [doi]
LID - 1012
AB  - Liver cancer, comprising hepatocellular carcinoma (HCC) and cholangiocarcinoma 
      (CCA), is a leading cause of cancer-related deaths worldwide. The liver is a 
      primary metabolic organ for progesterone (PRG) and PRG exerts its effects through 
      classic nuclear PRG receptors (nPRs) and non-classic membrane PRG receptors 
      (mPRs) or a combination of both. Previous studies have shown that the CCM 
      signaling complex (CSC) couples both nPRs and mPRs to form the CmPn 
      (CSC-mPR-PRG-nPR) signaling network, which is involved in multiple cellular 
      signaling pathways, including tumorigenesis of various cancers. Despite advances 
      in treatment, 5-year survival rates for liver cancer patients remain low, largely 
      due to the chemoresistant nature of HCCs. The lack of sensitive and specific 
      biomarkers for liver cancer diagnosis and prognosis emphasizes the need for 
      identifying new potential biomarkers. We propose the potential use of CmPn 
      members' expression data as prognostic biomarkers or biomarker signatures for the 
      major types of hepatic cancer, including HCCs and CCAs, as well as rare subtypes 
      such as undifferentiated pleomorphic sarcoma (UPS) and hepatic angiosarcoma 
      (HAS). In this study, we investigated the CmPn network through RNAseq data and 
      immunofluorescence techniques to measure alterations to key cancer pathways 
      during liver tumorigenesis. Our findings reveal significant differential 
      expression of multiple CmPn members, including CCM1, PAQR7, PGRMC1, and nPRs, in 
      both HCCs and CCAs, highlighting the crucial roles of mPRs, nPRs, and CSC 
      signaling during liver tumorigenesis. These key members of the CmPn network may 
      serve as potential biomarkers for the diagnosis and prognosis of liver cancer 
      subtypes, including rare subtypes.
FAU - Abou-Fadel, Johnathan
AU  - Abou-Fadel J
AD  - Department of Molecular and Translational Medicine (MTM), Texas Tech University 
      Health Science Center El Paso, El Paso, TX 79905, USA.
FAU - Reid, Victoria
AU  - Reid V
AUID- ORCID: 0000-0002-9670-2116
AD  - Department of Molecular and Translational Medicine (MTM), Texas Tech University 
      Health Science Center El Paso, El Paso, TX 79905, USA.
FAU - Le, Alexander
AU  - Le A
AD  - Department of Molecular and Translational Medicine (MTM), Texas Tech University 
      Health Science Center El Paso, El Paso, TX 79905, USA.
FAU - Croft, Jacob
AU  - Croft J
AD  - Department of Molecular and Translational Medicine (MTM), Texas Tech University 
      Health Science Center El Paso, El Paso, TX 79905, USA.
FAU - Zhang, Jun
AU  - Zhang J
AUID- ORCID: 0000-0002-4379-3616
AD  - Department of Molecular and Translational Medicine (MTM), Texas Tech University 
      Health Science Center El Paso, El Paso, TX 79905, USA.
LA  - eng
GR  - 1R21NS061191/GF/NIH HHS/United States
GR  - JZ/Coldwell foundation/
PT  - Journal Article
DEP - 20230307
PL  - Switzerland
TA  - Diagnostics (Basel)
JT  - Diagnostics (Basel, Switzerland)
JID - 101658402
PMC - PMC10047786
OTO - NOTNLM
OT  - CCM signaling complex (CSC)
OT  - biomarkers
OT  - classic nuclear progesterone receptors
OT  - immunological subtypes
OT  - liver cancer
OT  - liver cancer subtypes
OT  - mPRs-PRG-nPRs (CmPn) and CSC-mPRs-PRG (CmP) signaling network
OT  - non-classic membrane progesterone receptors
OT  - progesterone
OT  - tumorigenesis
COIS- The authors declare that there is no conflict of interest regarding the 
      publication of this article.
EDAT- 2023/03/30 06:00
MHDA- 2023/03/30 06:01
PMCR- 2023/03/07
CRDT- 2023/03/29 01:24
PHST- 2023/01/27 00:00 [received]
PHST- 2023/02/23 00:00 [revised]
PHST- 2023/03/05 00:00 [accepted]
PHST- 2023/03/30 06:01 [medline]
PHST- 2023/03/29 01:24 [entrez]
PHST- 2023/03/30 06:00 [pubmed]
PHST- 2023/03/07 00:00 [pmc-release]
AID - diagnostics13061012 [pii]
AID - diagnostics-13-01012 [pii]
AID - 10.3390/diagnostics13061012 [doi]
PST - epublish
SO  - Diagnostics (Basel). 2023 Mar 7;13(6):1012. doi: 10.3390/diagnostics13061012.